Azitra, Inc. reported its financial results for the second quarter and first half of 2026, revealing a net loss of $3.35 million for the three months ending June 30, 2026, compared to a loss of $2.89 million for the same period in 2025. For the first half of 2026, the company recorded a net loss of $7.27 million, up from $5.96 million in the prior year. Total operating expenses for the second quarter increased by 19% to $3.42 million, driven primarily by a 41% rise in general and administrative costs, which reached $2.07 million. Research and development expenses slightly decreased by 4% to $1.35 million, reflecting ongoing clinical trial activities.
The company experienced significant changes in its financial position compared to the previous fiscal period. As of June 30, 2026, Azitra reported total assets of approximately $8.92 million, a substantial increase from $5.03 million at the end of 2025. Cash and cash equivalents rose to $6.73 million, up from $2.07 million at the end of the previous year. This increase in liquidity was bolstered by financing activities that generated $10.58 million in cash during the first half of 2026, primarily from a private placement and draws on an equity line of credit.
Strategically, Azitra has made notable advancements in its product development pipeline, focusing on precision dermatology therapies. The company is advancing several key programs, including ATR-01, which targets ichthyosis vulgaris, and ATR-04, aimed at treating skin rashes in cancer patients undergoing specific therapies. The company has also received FDA clearance for clinical trials and is actively pursuing partnerships to enhance its research capabilities. As of June 30, 2026, Azitra had 60,603,742 shares of common stock outstanding, reflecting its recent capital-raising efforts.
Operationally, Azitra's research and development activities are supported by a proprietary microbial library of approximately 1,500 unique bacterial strains, which the company is leveraging to develop innovative therapies. The company has also established collaborations with leading academic institutions to enhance its research capabilities. However, Azitra continues to face challenges, including the need for additional funding to support ongoing operations and the potential risk of non-compliance with NYSE American listing standards, which could impact its market position.
Looking ahead, Azitra's management has expressed a commitment to securing additional financing to support its operations and product development initiatives. The company is focused on expanding its portfolio of product candidates while navigating the complexities of clinical trials and regulatory requirements. Despite the challenges, Azitra remains optimistic about its strategic direction and the potential for its innovative therapies in the dermatology market.
About Azitra, Inc.
Azitra, Inc. is a clinical-stage biopharmaceutical company developing precision dermatology therapies using engineered proteins and live biotherapeutic products derived from a proprietary microbial library of over 1,500 bacterial strains. Focusing on genetically engineered Staphylococcus epidermidis, Azitra creates topical treatments targeting rare and chronic skin diseases, leveraging AI-driven strain screening and licensed genetic engineering technologies to deliver therapeutic proteins directly into the skin for improved disease management.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov